Glucagon Market Size, Share, Growth, And Industry Analysis by Type (Inject Glucagon and Nasal Glucagon) by Application (Emergency Kits, General Use, Diagnostic & Motility, Cardiogenic Shock and Others), Regional Insights, and Forecast To 2032

• 

   Request a Free Sample To Get More Information on this Market

Glucagon Market Report Overview

The global glucagon market size was valued at USD 0.59 billion in 2023 and is projected to grow from USD 0.59 billion in 2024 to USD 0.95 billion by 2032, exhibiting a CAGR of 6.1% during the forecast period. Asia-Pacific holds leading position in glucagon market share in 2023.

The hormone glucagon mobilises the glucose in the circulation by converting glycogen to glucose. The absence of this hormone results in hypoglycaemia, a disorder. Injections of glycogen and oral medications are given to patients who have hypoglycemia. Glucose injections are used to diagnose patients as well as treat severe hypoglycemia. Reduced intestinal motility is used in diagnostic radiography examinations of the small intestine, duodenum, colon, and stomach where it may be beneficial. An increase in the prevalence of type 1 and type 2 diabetes, the development of new products, and consumer misunderstanding about hypoglycemia are the main factors driving the glucagon market size are used to diagnose and treat severe hypoglycemia. Due to the rising incidence of diabetes, lack of knowledge of hypoglycemia, and new product releases by market participants, it is projected that glucagon market share will expand.

The rising incidence of hypoglycemia among diabetics is one of the main factors driving the expansion of the worldwide glucagon market size. The key development observed in the worldwide glucagon market is the increasing focus of market participants on the development of novel products, such as non-injectable emergency glucagon. Furthermore, the worldwide glucagon market is projected to have profitable growth prospects due to the development of cutting-edge medications and therapies to treat hypoglycemia.

COVID-19 Impact: Lockdown's Restrictions on Mobility and Supply Chain Disruptions Temporarily Hampered the Market Growth

The global COVID-19 pandemic has been unprecedented and staggering, with glucagon market experiencing higher-than-anticipated demand across all regions compared to pre-pandemic levels. The sudden rise in CAGR is attributable to the market's growth and demand returning to pre-pandemic levels once the pandemic is over.

The spread of the Glucagon business was helped by the Covid-19 pandemic. Those with diabetes were more likely to show severe virus-related symptoms than those without diabetes. The requirement for glucagon increased as a result in order to maintain steady blood sugar levels. The product supply, however, was momentarily impeded due to the lockdown's limitations on movement and supply chain disruptions. The glucagon market has been altered by the COVID-19. Research and development were primarily focused on COVID because of the pandemic. This change has an impact on the study of glucagon injectables. Additionally, as lifestyle and eating patterns have changed, so has the prevalence of diabetes. Consequently, persons are more likely to develop diabetes and hypoglycemia. Therefore, COVID-19 has both favourable and unfavorable effects on the glucagon market growth. 

Latest Trends

"Creation of New Distribution Methods and Increased Usage of social media for Awareness-Raising"

The desire to give patients more practical and user-friendly alternatives is what spurs the development of innovative glucagon delivery systems. The creation of wearable gadgets that can continuously give insulin is a special area of interest. These gadgets offer more constant glucose management by imitating the body's natural insulin delivery mechanism. Another significant market trend is the growing use of social media to highlight the significance of glucose management. Patients and caregivers use social media sites like Twitter and Facebook to exchange information on managing diabetes. This is assisting in bringing attention to the significance of glucose management and the requirement for efficient remedies. 

 Request a Free Sample To Get Analysis on Key Segments on this Market

Glucagon Market Segmentation

• By type

Depending on glucagon market given are types: Inject Glucagon and Nasal Glucagon. The inject glucagon type will capture the maximum market share through 2028.

• By Application

The market is divided in emergency kits, general use, diagnostic & motility, cardiogenic shock and others based on application. The global glucagon market players in cover segment like emergency kits will dominate the market share during 2022-2028.

Driving Factors

"The Growing Incidence of Diabetes and the Growing Need for Cutting-Edge Treatments are Driving Market Growth "

Globally, those in charge of public health are quite concerned about the rising incidence of diabetes. Diabetes prevalence has increased dramatically in recent years as a result of diabetes becoming a serious cause of death and disability. The glucagon market growth is primarily driven by the expanding demand for cutting-edge treatments. The hormone glucagon, which helps to regulate blood sugar levels, is secreted by the pancreas. In order to cure diabetes, it elevates blood sugar levels. The glucagon market share is expected to grow significantly over the next years as the prevalence of diabetes continues to rise and there is an increased need for cutting-edge medical treatments.

"Growing Consumer Awareness of the Necessity of Glucose Control to Drive Market Growth "

The number of diabetics who have problems from the condition has decreased as a result of rising glucose management knowledge and the availability of novel delivery systems. Among the past, problems including heart disease, stroke, and renal disease were more common in patients with diabetes. People with diabetes can now better regulate their blood sugar levels thanks to the development of innovative delivery systems like insulin pumps and continuous glucose monitoring. This thus lowers the possibility of getting diabetes-related problems. The significance of glucose control in the treatment of diabetes has come to light in recent years. As a result, innovative glucagon administration systems, including pen injectors and pre-filled syringes, have been created. These innovative delivery systems give a more constant dosage of glucagon and are more practical and simpler to use than conventional injectors.

Restraining Factors

"Lack of Public Understanding of the Significance of Glucose Management Might be Limiting the Market's Growth"

The glucagon market is constrained by the general public's ignorance of the importance of glucose management. There is not a large market for glucagon medicines since many diabetics are ignorant of the need of maintaining normal blood sugar levels. The prospective glucagon market growth is constrained by the general public's ignorance of the importance of glucose regulation. Many people are still unaware of how glucagon regulates blood sugar levels, despite the growing awareness of the importance of treating diabetes. Therefore, it is probable that the only people who can buy glucagon medications are those who already have diabetes or are at danger of getting it. The widespread public's ignorance of the significance of glucose regulation places a ceiling on the worldwide glucagon market share. Diabetes is underdiagnosed as a result of lack of knowledge, which also lowers the need for glucagon products. Another issue restricting glucagon market size is the high price of glucagon medicines.

• 

   Request a Free Sample To Get Analysis on Major Geographic Market
•  

Glucagon Market Regional Insights

"North America will Dominate the Industry Due to its Widespread Awareness "

North America holds the largest market share for glucagon market due to the rising incidence of hypoglycemia in diabetes patients, the rise in the number of patients seeking treatment for it in emergency rooms, the rise in the incidence rate in neonates and children, the rise in patients with hypoglycemia brought on by other diseases, and the introduction of nasal glucagon with better clinical outcomes. Additionally, rising public awareness and product approvals by regulatory bodies have supported glucagon market growth. 

The market for glucagon treatment is dominated by Europe, the world's second-largest market. Due to the availability of state-of-the-art treatment facilities, highly qualified technical personnel, and government funding for research & development, the Europe glucagon market share is anticipated to grow significantly over the course of the anticipated time period. Due to rising rates of hypoglycemia in people with diabetes and the establishment of new hospitals and clinics, the Europe region's glucagon market has had the fastest rate of growth.

Key Industry Players

"Key Players Focus on Partnerships to Gain a Competitive Advantage "

Prominent market players are making collaborative efforts by partnering with other companies to stay ahead of the competition. Many companies are also investing in new product launches to expand their product portfolio. Mergers and acquisitions are also among the key strategies used by players to expand their product portfolios.

LIST OF TOP GLUCAGON COMPANIES

• Novo Nordisk (Denmark)
• Eli Lilly (U.S)
• Fresenius Kabi (Germany)
• Torrent Labs (India)
• Taj Pharmaceuticals (India)
• Xeris Pharmaceuticals (U.S)

Report Coverage

This research profiles a report with extensive studies that take into description the firms that exist in the market affecting the forecasting period. With detailed studies done, it also offers a comprehensive analysis by inspecting the factors like segmentation, opportunities, industrial developments, trends, growth, size, share, and restraints. This analysis is subject to alteration if the key players and probable analysis of market dynamics change.